Broad Institute and Northwestern University researchers are encouraging others to examine non-coding genes, when ...
About 500 children worldwide have received the gene therapy, including some families traveling abroad to gain access to it.
The firm will put the funds toward advancing its autologous CAR T-cell therapy MB-105 into Phase II clinical trials in CD5-positive lymphoma.
The strategic shift will allow the firm to focus on advancing a newly announced in vivo gene-editing therapy candidate that's in preclinical development.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback